Oric Pharmaceuticals (ORIC) to Release Quarterly Earnings on Monday

Key Points

• Oric Pharmaceuticals is set to announce its Q2 2025 earnings on August 11, with analysts predicting a loss of $0.46 per share for the quarter.
• Recent analyst ratings show an average rating of "Buy" for Oric Pharmaceuticals, with a price target averaging $18.57, reflecting positive sentiment towards the company's growth prospects.
• Insider activity includes Director Angie You purchasing 26,597 shares at $9.39 per share, while CFO Dominic Piscitelli sold 32,466 shares at $10.50, indicating mixed signals on insider confidence.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($0.46) per share for the quarter.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.42) earnings per share for the quarter, beating analysts' consensus estimates of ($0.51) by $0.09. On average, analysts expect Oric Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Oric Pharmaceuticals Stock Performance

Shares of NASDAQ:ORIC traded down $0.39 during trading on Friday, hitting $9.24. The company's stock had a trading volume of 1,049,844 shares, compared to its average volume of 1,127,561. The company has a market capitalization of $787.43 million, a PE ratio of -4.94 and a beta of 1.69. Oric Pharmaceuticals has a fifty-two week low of $3.90 and a fifty-two week high of $14.67. The business has a 50 day moving average price of $10.21 and a two-hundred day moving average price of $8.14.

Insider Buying and Selling

In other Oric Pharmaceuticals news, Director Angie You purchased 26,597 shares of Oric Pharmaceuticals stock in a transaction that occurred on Friday, June 20th. The stock was purchased at an average price of $9.39 per share, for a total transaction of $249,745.83. Following the transaction, the director directly owned 26,597 shares in the company, valued at $249,745.83. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Dominic Piscitelli sold 32,466 shares of the firm's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $10.50, for a total transaction of $340,893.00. Following the transaction, the chief financial officer directly owned 68,317 shares in the company, valued at $717,328.50. The trade was a 32.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 40,000 shares of company stock worth $416,289. Insiders own 6.82% of the company's stock.

Institutional Trading of Oric Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. Creative Planning purchased a new stake in shares of Oric Pharmaceuticals during the second quarter worth approximately $113,000. Jane Street Group LLC increased its stake in Oric Pharmaceuticals by 56.0% in the 1st quarter. Jane Street Group LLC now owns 31,198 shares of the company's stock valued at $174,000 after buying an additional 11,198 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Oric Pharmaceuticals by 8.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company's stock worth $226,000 after buying an additional 3,131 shares during the last quarter. AQR Capital Management LLC acquired a new stake in shares of Oric Pharmaceuticals in the 1st quarter worth $276,000. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Oric Pharmaceuticals by 9.2% in the first quarter. Goldman Sachs Group Inc. now owns 294,784 shares of the company's stock valued at $1,645,000 after acquiring an additional 24,778 shares in the last quarter. 95.05% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently issued reports on ORIC shares. Oppenheimer decreased their price target on shares of Oric Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. LADENBURG THALM/SH SH started coverage on Oric Pharmaceuticals in a research note on Tuesday, July 8th. They issued a "buy" rating and a $15.00 price target on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Oric Pharmaceuticals in a research report on Tuesday, May 6th. Wedbush reissued an "outperform" rating and set a $20.00 target price on shares of Oric Pharmaceuticals in a research report on Monday, June 23rd. Finally, HC Wainwright restated a "buy" rating and set a $21.00 target price on shares of Oric Pharmaceuticals in a research note on Monday, May 5th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, Oric Pharmaceuticals presently has a consensus rating of "Buy" and a consensus price target of $18.57.

Oric Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.